Abbott Acquires Rights for PanGenetics’ Analgesic
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 11 (Table of Contents)
Published: 25 Nov-2009
DOI: 10.3833/pdr.v2009.i11.1276 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
As part of its strategy to expand its pipeline in drugs tackling chronic pain, Abbott Laboratories purchased worldwide rights for a humanized antibody against nerve growth factor (NGF), PG110, from PanGenetics BV in deal valued at US$170 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS